Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

November 15, 2021

Study Completion Date

November 30, 2026

Conditions
AML/MDS
Interventions
DRUG

Decitabine

Decitabine dosage 20mg/m2 i.v.

DRUG

Midostaurin

Midostaurin 50 mg b.i.d.

Trial Locations (37)

Unknown

BE-Antwerpen-ZNASTUIVENBERG, Antwerp

BE-Haine-Saint-Paul-JOLIMONT, Haine-Saint-Paul

BE-Roeselare-AZDELTA, Roeselare

DE-Magdeburg-OVGU, Magdeburg

NL-Den Bosch-JBZ, 's-Hertogenbosch

NL-Amersfoort-MEANDERMC, Amersfoort

NL-Amsterdam-OLVG, Amsterdam

NL-Amsterdam-VUMC, Amsterdam

NL-Arnhem-RIJNSTATE, Arnhem

NL-Breda-AMPHIA, Breda

NL-Delft-RDGG, Delft

NL-Doetinchem-SLINGELAND, Doetinchem

NL-Dordrecht-ASZ, Dordrecht

NL-Ede-ZGV, Ede

NL-Eindhoven-CATHARINA, Eindhoven

NL-Eindhoven-MAXIMAMC, Eindhoven

NL-Enschede-MST, Enschede

NL-Groningen-UMCG, Groningen

NL-Leeuwarden-MCL, Leeuwarden

NL-Maastricht-MUMC, Maastricht

NL-Nieuwegein-ANTONIUS, Nieuwegein

NL-Nijmegen-CWZ, Nijmegen

NL-Nijmegen-RADBOUDUMC, Nijmegen

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Den Haag-HAGA, The Hague

NL-Utrecht-UMCUTRECHT, Utrecht

NL-Zwolle-ISALA, Zwolle

CH-Aarau-KSA, Aarau

CH-Basel-USB, Basel

CH-Bellinzona-IOSI, Bellinzona

CH-Bern-INSEL, Bern

CH-Fribourg-HFR, Fribourg

CH-Geneve (14)-HCUGE, Geneva

CH-Lausanne-CHUV, Lausanne

CH-Luzern-LUKS, Lucerne

CH-St. Gallen-KSSG, Sankt Gallen

CH-Zürich-USZ, Zurich

All Listed Sponsors
collaborator

Swiss Cancer Institute

OTHER

lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER